Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) just unveiled an announcement.
Shanghai Junshi Biosciences Co., Ltd. announced that its chairman, Mr. Xiong Jun, plans to increase his shareholding in the company by at least RMB100 million, with a minimum of RMB50 million allocated to A shares. As of October 2025, the shareholding increase plan has reached its midpoint, but due to various factors such as reporting windows and funding arrangements, the increase has not yet been completed. Mr. Xiong Jun intends to continue with the shareholding increase plan as opportunities arise, which may impact the company’s market position and shareholder confidence.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$34.70 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in China, primarily engaged in the research, development, and commercialization of innovative therapies. The company focuses on treatments for cancer, autoimmune, and other serious diseases, positioning itself as a leader in the biopharmaceutical industry.
Average Trading Volume: 12,110,796
Technical Sentiment Signal: Buy
Current Market Cap: HK$42.93B
See more insights into 1877 stock on TipRanks’ Stock Analysis page.